Stay updated with breaking news from Servier Group. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Wide range of research across tumor types underscores Servier's commitment to discovering novel approaches to addressing difficult-to-treat cancers Phase 3...
/PRNewswire/ -- Servier, a leader in oncology committed to bringing the promise of tomorrow to the patients we serve, today announced that the U.S. Food and...
TIBSOVO is the first therapy targeting cancer metabolism approved in combination with azacitidine for patients with newly diagnosed IDH1-mutated acute myeloid leukemia FDA approval based
/PRNewswire/ -- Servier, a leader in oncology committed to bringing the promise of tomorrow to the patients we serve, today announced that the U.S. Food and...
- TIBSOVO is an inhibitor of the mutated isocitrate dehydrogenase-1(IDH1) enzyme - TIBSOVO is the first IDH1 mutation specific targeted therapy submitted in Europe - The submission